This is spring loaded waiting to go off. $40-50m mc is nothing if any one of there immunotherapies are shown to either work as a standalone product or help other pharma companies drugs work much more effectively. IMU got to a $3b mc on zero revenue. All the small biotech have pulled back, but the tide may turn just as we show positive results. I'm staying in.
Ann: CBCF funding to support deoxymab brain cancer development, page-6
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.425K | 1.058M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 29432066 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |